您的当前位置:首页 > 行业数据 > CD19靶向CAR-T(IntasPharmaceuticals)针对SSc患者临床疗效初显,整体安全性较好
图片属性
图片格式:PNG 图片大小:132KB 图片尺寸:2327*518
同报告图片
 / 4
CD19靶向CAR-T(IntasPharmaceuticals)针对SSc患者临床疗效初显,整体安全性较好_第1页
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
CD19靶向CAR-T(IntasPharmaceuticals)针对SSc患者临床疗效初显,整体安全性较好_第2页
CD19靶向CAR-T(IntasPharmaceuticals)针对SSc患者临床疗效初显,整体安全性较好_第3页
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
CD19靶向CAR-T(IntasPharmaceuticals)针对SSc患者临床疗效初显,整体安全性较好_第4页
CD19靶向CAR-T(IntasPharmaceuticals)针对SSc患者临床疗效初显,整体安全性较好_第5页
所属报告: 生物制品行业深度报告:双抗&CAR-T:新一代BCDT疗法新星进军千亿自免蓝海市场-241207(17页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠